BioSpace News Archive

Park City Group, Inc. (NASDAQ: PCYG), the parent company of ReposiTrak, Inc., which operates a B2B ecommerce, compliance, and supply chain platform that partners with retailers, wholesalers, and their suppliers, to accelerate sales, control risk, and improve supply chain efficiencies, announced financial results for the fourth fiscal quarter and fiscal year ended June 30, 2019.

We are proud to announce that Dr. Sanford Moretsky and Dr. Craig Cassidy, of Valley Eye Specialists, were amongst the first select group of eye surgeons nationally to implant the Alcon AcrySof® IQ PanOptix® Trifocal Intraocular Lens, after FDA approval.

SightGlass Vision, Inc., today announced that baseline data from CYPRESS, the Company’s pivotal trial assessing the safety and efficacy of novel lenses designed to control nearsightedness in children, will be presented at the 17th International Myopia Conference 2019, held September 12 to 15, 2019 in Tokyo, Japan

Tower Health announced today that a new Tower Health Transplant Institute has been organized and will become the new home for the nationally recognized kidney and liver transplant program formerly located at Hahnemann University Hospital.

Rallybio LLC, a development-stage biotechnology company, today announced that it has broadened its drug development capabilities with the addition of Douglas Sheridan, PhD. Dr. Sheridan, a seasoned R&D leader, has significant drug development experience, including discovery, strategic planning and clinical program management.

Technology Executive Will Help Deliver Innovative, Quality Solutions to Clients

Lighter, Slimmer Laryngoscopes Allow Physicians and Therapists Greater Visualization of Key Anatomy

SilverCloud Health, the world’s leading digital mental health platform, today announced the addition of five renowned mental health experts to the company’s clinical advisory board.

HeartFlow, Inc. today announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non-invasive, real-time virtual modeling tool for coronary artery disease (CAD) intervention.

MedPharm Holdings (“MedPharm”), reiterated today its formal policy prohibiting the use of suspected unsafe chemical additives to its entire line of cannabis products, most notably its concentrates that are used in vape products